[{"orgOrder":0,"company":"C4 Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"CFT1946","moa":"BiDAC","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"C4 Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"C4 Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"C4 Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"C4 Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"CFT1946","moa":"||BiDAC","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"C4 Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"C4 Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"C4 Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"C4 Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"CFT1946","moa":"BiDAC","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"C4 Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"C4 Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"C4 Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"C4 Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"CFT8634","moa":"Bromodomain-9","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"C4 Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"C4 Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"C4 Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"C4 Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"CFT8634","moa":"Bromodomain-9","graph1":"Oncology","graph2":"IND Enabling","graph3":"C4 Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"C4 Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"C4 Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"C4 Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"CFT8634","moa":"Bromodomain-9","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"C4 Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"C4 Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"C4 Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"C4 Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Cemsidomide","moa":"Cereblon","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"C4 Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"C4 Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"C4 Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"C4 Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"CFT8919","moa":"EGFR L858R","graph1":"Oncology","graph2":"Phase I","graph3":"C4 Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"C4 Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"C4 Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"C4 Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"CFT8919","moa":"EGFR L858R","graph1":"Oncology","graph2":"Phase I","graph3":"C4 Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"C4 Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"C4 Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"C4 Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"CFT8919","moa":"EGFR L858R","graph1":"Oncology","graph2":"Phase I","graph3":"C4 Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"C4 Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"C4 Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"C4 Therapeutics","sponsor":"Betta Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Financing","leadProduct":"CFT8919","moa":"EGFR L858R","graph1":"Oncology","graph2":"Phase I","graph3":"C4 Therapeutics","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.029999999999999999,"dosageForm":"Undisclosed","sponsorNew":"C4 Therapeutics \/ Betta Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"C4 Therapeutics \/ Betta Pharmaceuticals"},{"orgOrder":0,"company":"C4 Therapeutics","sponsor":"Betta Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Licensing Agreement","leadProduct":"CFT8919","moa":"EGFR L858R","graph1":"Oncology","graph2":"Phase I","graph3":"C4 Therapeutics","amount2":0.39000000000000001,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.39000000000000001,"dosageForm":"Undisclosed","sponsorNew":"C4 Therapeutics \/ Betta Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"C4 Therapeutics \/ Betta Pharmaceuticals"},{"orgOrder":0,"company":"C4 Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"CFT7455","moa":"||IKZF1\/IKZF3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"C4 Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"C4 Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"C4 Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"C4 Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"CFT7455","moa":"||IKZF1\/IKZF3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"C4 Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"C4 Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"C4 Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"C4 Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"CFT7455","moa":"||IKZF1\/IKZF3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"C4 Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"C4 Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"C4 Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"C4 Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"CFT7455","moa":"||IKZF1\/IKZF3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"C4 Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"C4 Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"C4 Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"C4 Therapeutics","sponsor":"Biogen","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Collaboration","leadProduct":"BIIB142","moa":"IRAK4","graph1":"Immunology","graph2":"IND Enabling","graph3":"C4 Therapeutics","amount2":0.41999999999999998,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0.41999999999999998,"dosageForm":"Undisclosed","sponsorNew":"C4 Therapeutics \/ Biogen","highestDevelopmentStatusID":"5","companyTruncated":"C4 Therapeutics \/ Biogen"},{"orgOrder":0,"company":"C4 Therapeutics","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Termination","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"C4 Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"C4 Therapeutics \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"4","companyTruncated":"C4 Therapeutics \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"C4 Therapeutics","sponsor":"Merck Group","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"C4 Therapeutics","amount2":0.76000000000000001,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0.76000000000000001,"dosageForm":"Undisclosed","sponsorNew":"C4 Therapeutics \/ Merck Group","highestDevelopmentStatusID":"4","companyTruncated":"C4 Therapeutics \/ Merck Group"},{"orgOrder":0,"company":"C4 Therapeutics","sponsor":"Biogen","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Discovery","graph3":"C4 Therapeutics","amount2":0.41999999999999998,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","amount2New":0.41999999999999998,"dosageForm":"Undisclosed","sponsorNew":"C4 Therapeutics \/ Biogen","highestDevelopmentStatusID":"2","companyTruncated":"C4 Therapeutics \/ Biogen"},{"orgOrder":0,"company":"C4 Therapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"C4 Therapeutics","amount2":0.60999999999999999,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0.60999999999999999,"dosageForm":"Undisclosed","sponsorNew":"C4 Therapeutics \/ Merck & Co","highestDevelopmentStatusID":"4","companyTruncated":"C4 Therapeutics \/ Merck & Co"},{"orgOrder":0,"company":"C4 Therapeutics","sponsor":"Perceptive Advisors","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"C4 Therapeutics","amount2":0.17000000000000001,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0.17000000000000001,"dosageForm":"Undisclosed","sponsorNew":"C4 Therapeutics \/ Perceptive Advisors","highestDevelopmentStatusID":"4","companyTruncated":"C4 Therapeutics \/ Perceptive Advisors"},{"orgOrder":0,"company":"C4 Therapeutics","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Collaboration","leadProduct":"Cemsidomide","moa":"||Cereblon","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"C4 Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"C4 Therapeutics \/ Pfizer Inc","highestDevelopmentStatusID":"7","companyTruncated":"C4 Therapeutics \/ Pfizer Inc"},{"orgOrder":0,"company":"C4 Therapeutics","sponsor":"RA Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Public Offering","leadProduct":"Cemsidomide","moa":"Cereblon","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"C4 Therapeutics","amount2":0.13,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.13,"dosageForm":"Undisclosed","sponsorNew":"C4 Therapeutics \/ RA Capital Management","highestDevelopmentStatusID":"7","companyTruncated":"C4 Therapeutics \/ RA Capital Management"}]
Find Clinical Drug Pipeline Developments & Deals by C4 Therapeutics
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
